Article Details
Retrieved on: 2025-06-03 19:40:59
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses NXC-201, a CAR-T therapy showing promise for AL amyloidosis, which involves protein folding issues. It highlights FDA RMAT designation, linking it to advancements in US pharmaceuticals policy and regenerative medicine explored in Chicago.
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here